Enterprise Therapeutics has released peer-reviewed findings from a Phase 1 study of ETD001, their novel inhaled ENaC blocker designed to improve mucociliary clearance for cystic fibrosis (CF) patients. The report, published in The Journal of Cystic Fibrosis, highlights that ETD001 was well tolerated in healthy volunteers at doses higher than those anticipated to be therapeutic and capable of producing long-lasting benefits in airway hydration.
Key takeaways from the study include a strong concordance between ETD001’s behavior in preclinical models and in humans, reinforcing confidence in its pharmacokinetic profile. In particular, after inhaled administration, ETD001 exhibited slow absorption from the lungs into the systemic circulation, suggesting a potentially extended duration of action within the respiratory tract. Importantly, even with target engagement in the kidney potentially affecting potassium balance, potassium levels remained within normal limits across all tested doses.
The Phase 1 trial assessed safety, tolerability, and pharmacokinetics across single and multiple ascending inhaled doses, including regimens mimicking the doses projected to be efficacious in patients. ETD001 was tolerated well both as a single dose and with twice-daily dosing over a 14-day period. These human data align closely with preclinical observations, which documented safety and a longer-lasting lung effect lasting over 16 hours after a single inhaled dose.
Enterprise Therapeutics is advancing a Phase 2 trial (NCT06478706) to determine whether 28 days of ETD001 therapy can improve lung function in individuals with CF, with headline results anticipated in early 2026.
Dr. Henry Danahay, Head of Biology at Enterprise Therapeutics and lead author of the study, emphasized the urgent need for additional treatments to address mucus obstruction in CF, particularly for patients who do not respond to CFTR modulators. He noted the company’s commitment to developing therapies that could benefit all CF patients and expressed gratitude to trial participants and those enrolled in the ongoing Phase 2 study.
Cystic fibrosis affects an estimated 100,000 people worldwide and often leads to mucus buildup and recurrent lung infections, contributing to a gradual decline in lung function. ENaC inhibition in the airways aims to restore proper mucus hydration, which is expected to translate into meaningful improvements in pulmonary function.
Sources and references for the study and preclinical background are available through The Journal of Cystic Fibrosis and Enterprise Therapeutics’ official communications, including their preclinical profile of ETD001.
In sum, these Phase 1 results strengthen the case for ETD001 as a promising inhaled therapy for CF, with an encouraging safety and pharmacokinetic footprint and a clear path toward shedding light on its potential clinical benefits in the Phase 2 program.
Would this approach, if successful, reshape the standard of care for CF patients not eligible for CFTR modulators, or should emphasis remain on combination strategies that pair ENaC blockade with other mucus-modifying therapies?
